

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

**Cais Rhyddid Gwybodaeth / Freedom of Information request
Ein Cyf / Our Ref: 23-E-014**

You asked:

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

1. How many patients were treated in April 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinvo) - 0
- Baricitinib (Olumiant) - 25
- Dupilumab (Dupixent) - 34
- Omalizumab (Xolair) - 26
- Tralokinumab (Adtralza) - 5
- Upadacitinib (Rinvoq) - 0

2. How many patients were treated in April 2023 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra) - 32
- Dupilumab (Dupixent) - 0
- Mepolizumab (Nucala) - 17
- Omalizumab (Xolair) - 8
- Reslizumab (Cinnaero) - 0
- Tezepelumab (Tezspire) - 0

